Abgentis’ goal is to provide a new broad-spectrum IV/oral antibacterial to treat acute and chronic, life-threatening and drug-resistant infections. Based on a previously marketed but uncompetitive compound, Abgentis’ “fast-follower” programme will deploy unique insight into the structure-activity relationships, microbiology, pharmacology and efficacy of antibacterial DNA supercoiling inhibitors to rapidly re-engineer and optimise, to create an internationally competitive product. The keys to market penetration are the IV and oral bioavailability (enabling step-down therapy), the spectrum of activity including both Gram+ve and Gram-ve pathogens and the ultra-low spontaneous resistance frequency.

Status exits

Associated Fund Early Advantage Fund

Sector Medical / Biotechnology

Associated Team Members

Relevant News

Early Advantage Fund Invests £75,000 In Abgentis

8 October 2012 A company creating new treatments for life-threatening and drug-resistant bacterial infections has…

read more

Global DNA Gyrase Subunit B (EC Market Future Development...

Global DNA Gyrase Subunit B (EC Market Future Development with Top Companies are...

read more

Abgentis’ Lead programme demonstrates efficacy against multi-drug resistant Gram-negatives

GYR12, Abgentis' lead novobiocin analogue, in combination with colistin, is effective against colistin-resistant strains...

read more

Biological Evaluation of Benzothiazole Ethyl Urea Inhibitors of Bacterial Type...

Novel antibacterial programmes developed under the leadership of Lloyd Czaplewski when he was at...

read more

More Companies in Medical / Biotechnology

Your browser is out-of-date!

Update your browser to view this website correctly.Update my browser now